These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

217 related articles for article (PubMed ID: 37314165)

  • 1. Direct oral anticoagulants and their antagonists in perioperative practice.
    Levy JH; Mamoun N
    Curr Opin Anaesthesiol; 2023 Aug; 36(4):394-398. PubMed ID: 37314165
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Idarucizumab and factor Xa reversal agents: role in hospital guidelines and protocols.
    Huisman MV; Fanikos J
    Am J Emerg Med; 2016 Nov; 34(11S):46-51. PubMed ID: 27697438
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Specific antidotes against direct oral anticoagulants: A comprehensive review of clinical trials data.
    Tummala R; Kavtaradze A; Gupta A; Ghosh RK
    Int J Cardiol; 2016 Jul; 214():292-8. PubMed ID: 27082776
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Idarucizumab and Factor Xa Reversal Agents: Role in Hospital Guidelines and Protocols.
    Huisman MV; Fanikos J
    Am J Med; 2016 Nov; 129(11S):S89-S96. PubMed ID: 27569673
    [TBL] [Abstract][Full Text] [Related]  

  • 5. How can we reverse bleeding in patients on direct oral anticoagulants?
    Crowther M; Cuker A
    Kardiol Pol; 2019; 77(1):3-11. PubMed ID: 30338501
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Reversal agents for severe bleeding associated with direct oral anticoagulants].
    Giubilato S; Lucà F; Di Fusco SA; Amico F; Colivicchi F; Gulizia MM
    G Ital Cardiol (Rome); 2022 Oct; 23(10):734-745. PubMed ID: 36169124
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Reversal strategies in patients treated with direct oral anticoagulants.
    Gressenberger P
    Vasa; 2019 Aug; 48(5):389-392. PubMed ID: 30719950
    [No Abstract]   [Full Text] [Related]  

  • 8. Reversal agents for current and forthcoming direct oral anticoagulants.
    van Es N; De Caterina R; Weitz JI
    Eur Heart J; 2023 May; 44(20):1795-1806. PubMed ID: 36988142
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Current Strategies for the Management of Bleeding Associated with Direct Oral Anticoagulants and a Review of Investigational Reversal Agents.
    Kaide CG; Gulseth MP
    J Emerg Med; 2020 Feb; 58(2):217-233. PubMed ID: 31831187
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Reversal of direct oral anticoagulants: a practical approach.
    Shih AW; Crowther MA
    Hematology Am Soc Hematol Educ Program; 2016 Dec; 2016(1):612-619. PubMed ID: 27913536
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical Relevance of Preclinical and Clinical Studies of Four-Factor Prothrombin Complex Concentrate for Treatment of Bleeding Related to Direct Oral Anticoagulants.
    Sarode R; Welsby IJ; Hoffman M
    Ann Emerg Med; 2023 Sep; 82(3):341-361. PubMed ID: 37204347
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Discontinuation and Management of Direct-Acting Anticoagulants for Emergency Procedures.
    Levy JH
    Am J Med; 2016 Nov; 129(11S):S47-S53. PubMed ID: 27569675
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Management of Bleeding With Non-Vitamin K Antagonist Oral Anticoagulants in the Era of Specific Reversal Agents.
    Ruff CT; Giugliano RP; Antman EM
    Circulation; 2016 Jul; 134(3):248-61. PubMed ID: 27436881
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Andexanet alfa versus four-factor prothrombin complex concentrate for the reversal of apixaban- or rivaroxaban-associated intracranial hemorrhage: a propensity score-overlap weighted analysis.
    Costa OS; Connolly SJ; Sharma M; Beyer-Westendorf J; Christoph MJ; Lovelace B; Coleman CI
    Crit Care; 2022 Jun; 26(1):180. PubMed ID: 35710578
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Reversal agents for direct oral anticoagulants: considerations for hospital physicians and intensivists.
    Desai NR; Cornutt D
    Hosp Pract (1995); 2019 Aug; 47(3):113-122. PubMed ID: 31317796
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recommendations for the emergency management of complications associated with the new direct oral anticoagulants (DOACs), apixaban, dabigatran and rivaroxaban.
    Steiner T; Böhm M; Dichgans M; Diener HC; Ell C; Endres M; Epple C; Grond M; Laufs U; Nickenig G; Riess H; Röther J; Schellinger PD; Spannagl M; Veltkamp R
    Clin Res Cardiol; 2013 Jun; 102(6):399-412. PubMed ID: 23669868
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Direct (New) Oral Anticoagulants (DOACs): Drawbacks, Bleeding and Reversal.
    Karcioglu O; Zengin S; Ozkaya B; Ersan E; Yilmaz S; Afacan G; Abuska D; Hosseinzadeh M; Yeniocak S
    Cardiovasc Hematol Agents Med Chem; 2022; 20(2):103-113. PubMed ID: 34521332
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Reversal of Newer Direct Oral Anticoagulant Drugs (DOACs).
    Hussain SS; Tyroch AH; Mukherjee D
    Cardiovasc Hematol Agents Med Chem; 2017; 14(2):76-81. PubMed ID: 27215215
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of Elective Surgery and Emergent Bleeding with Direct Oral Anticoagulants.
    Kaatz S; Mahan CE; Nakhle A; Gunasekaran K; Ali M; Lavender R; Paje DG
    Curr Cardiol Rep; 2017 Oct; 19(12):124. PubMed ID: 29064044
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recommendations for the use of andexanet alfa in the management of bleeding in patients on oral factor Xa inhibitors in Switzerland: Guideline from the Working Party Hemostasis of the Swiss Society of Hematology.
    Angelillo-Scherrer A; Casini A; Studt JD; Gerber B; Alberio LA; Fontana P
    Swiss Med Wkly; 2023 Jul; 153():40113. PubMed ID: 37499160
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.